Research Topics
| David V SheehanSummaryAffiliation: University of South Florida Country: USA Publications
| Collaborators
|
Detail Information
Publications
Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorderDavid V Sheehan
Institute for Research in Psychiatry, Department of Psychiatry, University of South Florida, Tampa, FL 33613 4788, USA
J Clin Psychiatry 66:34-40. 2005..To assess the efficacy and tolerability of controlled-release paroxetine (paroxetine CR) in the treatment of adults with panic disorder...
Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)David V Sheehan
Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, 3515 East Fletcher Ave, Tampa, FL 33613 4706, USA
J Clin Psychiatry 71:313-26. 2010....- Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patientDavid V Sheehan
Clinical and Translational Science Institute, University of South Florida, College of Medicine, 3515 East Fletcher Ave, Tampa, FL 33613, USA
J Affect Disord 145:83-94. 2013..Anxiety disorders complicate the treatment of bipolar disorder but are seldom the focus of bipolar treatment studies... - Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarateDavid V Sheehan
College of Medicine, University of South Florida, Tampa, FL 33613, USA
Int Clin Psychopharmacol 27:239-48. 2012..In conclusion, quetiapine XR (50-300 mg/day) monotherapy better maintains overall functioning and sleep quality than placebo in patients with major depressive disorder... - An open-label study of tiagabine in panic disorderDavid V Sheehan
University of South Florida College of Medicine, Tampa, FL, USA
Psychopharmacol Bull 40:32-40. 2007..Only one patient discontinued tiagabine due to adverse events. These findings suggest that administration of tiagabine may be of little benefit in patients with panic disorder... - Current approaches to the pharmacologic treatment of anxiety disordersDavid V Sheehan
University of South Florida College of Medicine, Tampa, FL 33613, USA
Psychopharmacol Bull 40:98-109. 2007..Preliminary data suggest that tiagabine, the only available SGRI, may also be beneficial in the anxiety disorders. Further research on these novel agents in anxiety disorders is needed... - Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic featuresDavid V Sheehan
Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, Florida 33613, USA
Int Clin Psychopharmacol 24:61-86. 2009..Venlafaxine was not superior to fluoxetine or placebo in providing remission... - Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxietyDavid V Sheehan
University of South Florida College of Medicine, United States
J Affect Disord 115:376-85. 2009..Although second generation antipsychotics are being used with increasing frequency in bipolar patients, their anxiolytic effects have not been well studied in this population... - An evidence-based review of the clinical use of sertraline in mood and anxiety disordersDavid V Sheehan
University of South Florida College of Medicine, 3515 E Fletcher Avenue, Tampa, FL 33613, USA
Int Clin Psychopharmacol 24:43-60. 2009.... - The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorderDavid V Sheehan
Department of Psychiatry, University of South Florida College of Medicine, Tampa, Florida 33613, USA
Psychopharmacol Bull 40:63-81. 2007..These results must be viewed in the context of the study limitations including its small size, the lack of independence of groups in a switch study, and the limitations of the diary records used... - Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scaleDavid V Sheehan
University of South Florida, Tampa, Florida, USA
Int Clin Psychopharmacol 26:75-83. 2011..The study shows that functional remission does not always move in tandem with symptom remission and provides useful anchor points or rules of thumb for evaluating symptomatic and functional remission in MDD and GAD... - Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disordersDavid V Sheehan
University of South Florida College of Medicine, Tampa, Florida, USA
CNS Drugs 22:963-73. 2008.... - Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetineDavid V Sheehan
University of South Florida College of Medicine, Tampa, FL, USA
J Clin Psychopharmacol 24:544-8. 2004..Differences in costs were primarily driven by reduction in hospitalization expenditures... - Differences in total medical costs across the SSRIs for the treatment of depression and anxietyDavid V Sheehan
Department of Psychiatry and Behavioral Medicine, University of South Florida, 4202 E Fowler Avenue, Tampa, FL 33620, USA
Am J Manag Care 11:S354-61. 2005..Future studies should measure rates of adherence in relation to medical outcomes over an expanded time frame... 
Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disordersKeming Gao
Department of Psychiatry, Mood and Anxiety Clinic in the Mood Disorders Program, Case Western Reserve University School of Medicine, University Hospitals Case Medical Center, Cleveland, OH 44106, USA
Expert Rev Neurother 9:1147-58. 2009..However, in contrast to antidepressants and benzodiazepines, the long-term risk and benefit of atypical antipsychotics in the treatment of GAD is yet to be determined...- Improved tolerability and increased length of therapyDavid V Sheehan
University of South Florida, College of Medicine, USA
Manag Care 12:23-5. 2003 - The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorderDavid V Sheehan
University of South Florida College of Medicine, Tampa, FL, USA
Psychopharmacol Bull 42:5-22. 2009..Overall, the results elucidate the efficacy components and tolerability characteristics previously demonstrated for TzCOAD monotherapy for patients with MDD at the recommended daily dose of 300 mg... - Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetineDavid V Sheehan
College of Medicine, University of South Florida, Tampa, FL, USA
Hum Psychopharmacol 26:242-51. 2011.... - The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorderDavid V Sheehan
University of South Florida College of Medicine, Tampa, FL, USA
Curr Med Res Opin 24:2457-66. 2008..To examine the relationship between global functional impairment and the treatment of anxious symptoms and painful somatic symptoms (PSS) in patients with generalized anxiety disorder (GAD)... - Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability ScaleKathy Harnett Sheehan
University of South Florida College of Medicine, Tampa, FL 33613, USA
Int Clin Psychopharmacol 23:70-83. 2008..In addition, the percentages with endpoint scores of zero should be reported... - Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacyJeffery A Lieberman
Department of Psychiatry, Neurosciences Hospital, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7160, USA
Neuropsychopharmacology 30:445-60. 2005.... - The management of panic disorderDavid V Sheehan
University of South Florida Institute for Research in Psychiatry, Tampa 33613, USA
J Clin Psychiatry 63:17-21. 2002.... - Paroxetine treatment of generalized anxiety disorderDavid V Sheehan
College of Medicine, University of South Florida, Tampa, FL 33613 4788, USA
Psychopharmacol Bull 37:64-75. 2003..This article provides an overview of GAD and a discussion of studies of paroxetine treatment in this anxiety disorder... - Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamineR Douglas Shytle
Center for Aging and Brain Repair, Department of Neurosurgery, University of South Florida College of Medicine, 12901 Bruce B. Downs Boulevard, Tampa, FL 33613, USA
Depress Anxiety 16:89-92. 2002 - Impact of formulary restrictions on the cost-effectiveness of antidepressant treatmentDavid V Sheehan
Department of Psychiatry and Behavioral Medicine, University of South Florida College of Medicine, Tampa, FL, USA
Manag Care Q 10:21-31. 2002..Assessment of overall cost-effectiveness should not be limited by acquisition costs but should take total healthcare costs into consideration...